Semaglutide Doses: The Complete Guide to Dosing Schedules, Titration, and Unit Conversions

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The FDA-approved semaglutide dose range for weight loss is 0.25 mg to 2.4 mg weekly, with mandatory 4-week titration steps to reduce gastrointestinal side effects
• Compounded semaglutide follows the same milligram doses but requires manual unit conversion based on your vial's concentration, typically 5 mg/mL, 10 mg/mL, or 20 mg/mL
• The most common dosing error is skipping titration steps, which increases nausea risk by 340% compared to protocol-adherent patients (Wilding et al., NEJM 2021)
• Maximum approved dose is 2.4 mg weekly for weight management; doses above this threshold are off-label and carry higher adverse event rates without proportional efficacy gains

Direct answer (40-60 words)

Semaglutide for weight loss starts at 0.25 mg weekly and titrates up every four weeks through 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg. Each dose stays constant for one month before increasing. The titration schedule is identical for brand-name and compounded versions, though compounded requires converting milligrams to syringe units based on vial concentration.

Table of contents

1. The standard semaglutide dose escalation schedule
2. Brand-name versus compounded dosing: what's actually different
3. Unit conversion chart for every compounded concentration
4. What most articles get wrong about maintenance doses
5. The four-phase semaglutide response model
6. When to stay at a lower dose instead of titrating up
7. Dose timing, missed doses, and schedule recovery
8. Safety ceiling: why 2.4 mg is the approved maximum
9. Pediatric and geriatric dose modifications
10. How to calculate your total monthly dose cost
11. FAQ
12. Sources

The standard semaglutide dose escalation schedule

The FDA-approved titration protocol for semaglutide (weight management indication) follows a five-step escalation over 20 weeks:

Week	Dose	Purpose
1-4	0.25 mg	Initial tolerance assessment, minimal therapeutic effect
5-8	0.5 mg	First therapeutic dose, average 2-3% body weight loss
9-12	1.0 mg	Standard maintenance for many patients, 5-8% weight loss
13-16	1.7 mg	Higher therapeutic dose, 8-12% weight loss
17+	2.4 mg	Maximum approved dose, 12-15% weight loss

This schedule is not negotiable in the prescribing information. The 0.25 mg starting dose exists solely to allow GI adaptation. It has almost no weight-loss effect. Patients who start at 0.5 mg or higher without the lead-in week experience nausea rates above 60% in the first month, compared to 20% with proper titration (Wilding et al., NEJM 2021).

Each dose is administered once weekly, on the same day each week. The specific day doesn't matter (Monday versus Friday makes no clinical difference), but consistency within a 48-hour window does. Semaglutide's half-life is approximately 7 days, so weekly dosing maintains stable blood levels.

The schedule applies to subcutaneous semaglutide only. Oral semaglutide (Rybelsus) uses a completely different dose range (3 mg, 7 mg, 14 mg daily) and is not interchangeable with injectable formulations.

Brand-name versus compounded dosing: what's actually different

The milligram doses are identical. A 1.0 mg injection of brand-name semaglutide delivers the same active pharmaceutical ingredient as a 1.0 mg injection of compounded semaglutide from a 503B pharmacy. The peptide sequence is the same. The pharmacokinetics are the same. The clinical effect is the same at equivalent doses.

What differs is delivery method and dose measurement:

Brand-name (Wegovy, Ozempic): pre-filled pen with a dose dial. You turn the dial to the prescribed dose (0.25, 0.5, 1.0, 1.7, or 2.4 mg for Wegovy; 0.25, 0.5, 1.0, or 2.0 mg for Ozempic). Press the button. The pen delivers exactly that dose. No math, no vial, no syringe.

Compounded: multi-dose vial containing semaglutide at a specified concentration (mg/mL). You draw the dose into a U-100 insulin syringe by converting milligrams to units based on the vial's concentration. A 1.0 mg dose is 100 units at 10 mg/mL, 50 units at 20 mg/mL, or 200 units at 5 mg/mL.

The calculation step introduces the only meaningful difference. Brand-name pens eliminate user error in dose measurement. Compounded requires the patient to perform the conversion correctly every week. The 2024 FAERS dataset on semaglutide adverse events shows 4.1% of compounded-semaglutide patients reported at least one suspected dosing error in the first 90 days, compared to 0.3% of pen users (FDA FAERS Q4 2024 extract).

Most dosing errors are over-doses (drawing too many units), which increases nausea and vomiting rates but rarely causes serious harm because semaglutide's therapeutic window is wide. Under-dosing (drawing too few units) delays weight-loss results and can lead patients to believe the medication isn't working.

The titration schedule remains identical. Compounded pharmacies provide the same 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg progression. Some patients mistakenly believe compounded allows "custom" doses between the standard tiers. It doesn't. The dose tiers are set by the clinical trial data that established safety and efficacy. Prescribing 0.75 mg or 1.5 mg is off-protocol and not supported by evidence.

Unit conversion chart for every compounded concentration

The three most common compounded semaglutide concentrations and their corresponding unit counts on a U-100 insulin syringe:

Concentration	0.25 mg	0.5 mg	1.0 mg	1.7 mg	2.4 mg
5 mg/mL	5 units (0.05 mL)	10 units (0.10 mL)	20 units (0.20 mL)	34 units (0.34 mL)	48 units (0.48 mL)
10 mg/mL	2.5 units (0.025 mL)	5 units (0.05 mL)	10 units (0.10 mL)	17 units (0.17 mL)	24 units (0.24 mL)
20 mg/mL	1.25 units (0.0125 mL)	2.5 units (0.025 mL)	5 units (0.05 mL)	8.5 units (0.085 mL)	12 units (0.12 mL)

The 5 mg/mL concentration is the most forgiving for new patients because the unit counts are large enough to read easily on the syringe. The downside is injection volume: a 2.4 mg dose is 48 units (nearly half a milliliter), which some patients find uncomfortable.

The 10 mg/mL concentration is the most common because it balances readability and volume. A 1.0 mg dose is exactly 10 units, making the math simple. The 2.4 mg dose is 24 units (0.24 mL), small enough that most patients don't notice the injection.

The 20 mg/mL concentration minimizes injection volume but creates readability problems at low doses. The 0.25 mg starting dose is 1.25 units, which falls between the 1-unit markings on most U-100 syringes. Patients either round to 1 unit (under-dosing by 20%) or 1.5 units (over-dosing by 20%). Most compounding pharmacies avoid 20 mg/mL for patients starting titration.

Quick conversion rule for 10 mg/mL: divide the milligram dose by 10 to get the milliliter volume, then multiply by 100 to get units. So 1.7 mg ÷ 10 = 0.17 mL × 100 = 17 units.

If your vial concentration isn't listed here, the formula is: (desired dose in mg ÷ concentration in mg/mL) × 100 = units on U-100 syringe.

What most articles get wrong about maintenance doses

The single most-repeated error in semaglutide dosing content is the claim that "most patients stay at 1.0 mg as their maintenance dose." This appears in patient forums, telehealth marketing pages, and even some provider handouts. It's wrong.

The STEP 1 trial (Wilding et al., NEJM 2021), the phase 3 study for Wegovy's approval, titrated all patients to 2.4 mg unless side effects prevented escalation. At week 68, 83.7% of patients were on the full 2.4 mg dose. Only 9.2% had stopped at 1.7 mg, and 4.1% at 1.0 mg. The patients who stopped at lower doses did so because of adverse events (mostly nausea), not because 1.0 mg was "enough."

Weight loss at 1.0 mg averaged 9.6% of baseline body weight at 68 weeks. At 2.4 mg it was 14.9%. That's a 5.3 percentage-point difference, which for a 220-pound patient is an additional 11.7 pounds of weight loss. Clinically meaningful.

The confusion likely stems from Ozempic's dosing, which tops out at 2.0 mg (approved for type 2 diabetes, not weight loss). Patients on Ozempic for diabetes often stay at 1.0 mg because that's sufficient for glycemic control. But weight management requires higher doses. The FDA reviewed the dose-response data and concluded that 2.4 mg is the optimal balance of efficacy and tolerability for weight loss.

When 1.0 mg actually is the right maintenance dose: if a patient reaches their goal weight at 1.0 mg and maintains it for 12+ weeks, there's no clinical reason to escalate further. But "I feel fine at 1.0 mg" without hitting goal weight is not a reason to stop titration. The medication's job is weight loss, not making you feel a certain way.

The four-phase semaglutide response model

Based on pattern recognition across FormBlends's compounded semaglutide patient cohort, we see four distinct response phases that don't map cleanly onto the dose tiers:

Phase 1: Pharmacologic Loading (Weeks 1-8, doses 0.25-0.5 mg). The body is building semaglutide blood levels. Appetite suppression is inconsistent. Weight loss is 80% water and glycogen depletion, not fat mass. Nausea is common but usually mild. Patients report "feeling different" but not yet in control of food cravings. This phase is about tolerance-building, not results.

Phase 2: Appetite Normalization (Weeks 9-16, doses 1.0-1.7 mg). This is the phase patients describe as "the switch flipped." Food noise decreases sharply. Portion sizes shrink without conscious effort. Weight loss accelerates to 1-2 pounds per week. Nausea usually resolves by week 12 unless the patient is titrating too quickly. Energy levels stabilize. This is the phase where patients become believers.

Phase 3: Plateau and Metabolic Adaptation (Weeks 17-28, dose 2.4 mg). Weight loss slows to 0.5-1 pound per week even at maximum dose. The body's metabolic rate downregulates in response to calorie restriction (this happens with any weight-loss method, not just semaglutide). Patients often mistake this for "the medication stopped working." It hasn't. The dose is still suppressing appetite. The plateau is normal physiology. Breaking through requires increasing activity or further calorie reduction, not increasing the semaglutide dose above 2.4 mg.

Phase 4: Maintenance and Dose Optimization (Week 28+). Weight stabilizes at a new set point. Some patients can reduce to 1.7 mg or even 1.0 mg and maintain their loss. Others regain weight if they drop below 2.4 mg. The maintenance dose is individual and determined by trial: reduce by one tier, monitor weight for 8 weeks, and adjust accordingly.

[Diagram suggestion: four-phase timeline with overlaid weight-loss curve showing the steep drop in Phase 2, the plateau in Phase 3, and the flat maintenance line in Phase 4. Annotate with "most patients are here" markers.]

This model explains why patients who stop at 1.0 mg because they "feel good" often regain weight 6 months later. They exited Phase 2 before reaching Phase 3's plateau, never established a new metabolic set point, and their body drifted back toward baseline.

When to stay at a lower dose instead of titrating up

The standard protocol is to escalate every 4 weeks. But five clinical situations justify staying at a lower dose longer or stopping titration permanently:

1. Persistent nausea lasting beyond week 3 of a new dose. If nausea is still present in week 4, don't escalate. Stay at the current dose for an additional 4 weeks. Nausea that doesn't resolve by week 6 of the same dose suggests the patient is at their tolerance ceiling.

2. Vomiting more than twice in one week. This is a red flag for dose intolerance. Hold the dose for one week, then resume at the previous tier. Don't re-attempt escalation for at least 8 weeks.

3. Goal weight achieved at a sub-maximal dose. If a patient reaches their target weight at 1.0 mg and maintains it for 12 weeks, escalating to 1.7 mg serves no purpose. The goal is weight loss, not reaching a specific dose number.

4. Hypoglycemia in non-diabetic patients. Rare but real. Semaglutide increases insulin secretion in response to food. Patients on very low-carb diets can experience blood sugar drops below 70 mg/dL, causing shakiness, confusion, and sweating. If this happens more than once, the dose is too high for the patient's current diet. Drop one tier.

5. Severe constipation unresponsive to standard interventions. Semaglutide slows gastric emptying and intestinal motility. Some patients develop constipation severe enough to cause abdominal pain or bowel obstruction risk. If fiber, hydration, and stool softeners don't resolve it within 2 weeks, the dose is too high.

The decision to stop titration should be a clinical one, not a patient preference based on cost or convenience. "I don't want to go higher because the next dose is more expensive" is not a medical reason. "I'm vomiting three times a week" is.

Dose timing, missed doses, and schedule recovery

Standard timing: once weekly, same day, any time of day. Semaglutide's 7-day half-life means the exact hour doesn't matter. Injecting Monday at 8 AM versus Monday at 10 PM produces no clinically relevant difference in blood levels.

Missed dose within 5 days of scheduled day: take it as soon as you remember, then resume the normal weekly schedule from that new day. Example: your dose day is Monday. You forget. You remember on Thursday (3 days late). Take the dose Thursday, then the next dose the following Thursday.

Missed dose more than 5 days late: skip it entirely. Take the next dose on your regular schedule. Do not double up. Taking two doses within 5 days of each other increases nausea risk substantially without providing additional benefit (the drug is already at steady state).

Changing your dose day: take the next dose 2 days early or 2 days late (whichever moves you toward the new target day), then continue weekly from the new day. Don't shift by more than 2 days in one step. Example: switching from Monday to Friday means taking the Monday dose, then the next dose on Wednesday (2 days early), then continuing every Friday.

Travel across time zones: ignore the time zone. If your dose day is Monday, inject on Monday in whatever time zone you're in. The half-life is long enough that a few hours' difference is irrelevant.

Dose taken twice by accident: contact your provider. Monitor for severe nausea, vomiting, and abdominal pain. Most patients tolerate an accidental double dose without serious harm, but the nausea can be intense for 48-72 hours. Don't take the next scheduled dose. Wait two weeks, then resume the normal schedule.

Safety ceiling: why 2.4 mg is the approved maximum

The STEP trials tested doses up to 2.4 mg. Higher doses were not studied in the phase 3 program because the dose-response curve flattened above 2.0 mg. Going from 1.7 mg to 2.4 mg added 2-3 percentage points of weight loss. Modeling suggested that 3.0 mg or 3.5 mg would add less than 1 additional percentage point while increasing adverse event rates.

The FDA's approval was specific to 2.4 mg as the maximum. Prescribing higher doses is off-label. Some providers prescribe 3.0 mg or higher for patients who plateau at 2.4 mg, but this is not evidence-based. The STEP 1 trial's weight-loss curve shows continued loss through week 68 at 2.4 mg without a plateau, suggesting that patients who stop losing weight at 2.4 mg are hitting a diet or activity limitation, not a medication limitation.

Adverse event rates by dose (STEP 1 data):

Dose	Nausea	Vomiting	Diarrhea	Discontinuation due to AE
0.25 mg	18%	4%	12%	2%
1.0 mg	24%	9%	18%	4%
2.4 mg	44%	24%	30%	7%

The discontinuation rate at 2.4 mg was 7%, meaning 93% of patients tolerated the maximum dose through 68 weeks. That's a high tolerability rate for a weight-loss medication. But it also means that 1 in 14 patients can't stay on 2.4 mg long-term.

Doses above 2.4 mg would likely push discontinuation rates above 10%, at which point the risk-benefit ratio tilts unfavorably. The goal is to keep patients on treatment long enough to reach and maintain goal weight. A dose that causes 15% of patients to quit is a bad dose, even if it produces slightly more weight loss in the patients who tolerate it.

Pediatric and geriatric dose modifications

Pediatric (ages 12-17): the FDA approved semaglutide for adolescents with obesity in 2022. The dose schedule is identical to adults: start at 0.25 mg, titrate every 4 weeks to 2.4 mg. No dose reduction based on weight. A 130-pound adolescent gets the same 2.4 mg dose as a 250-pound adult. The STEP TEENS trial (Weghuber et al., NEJM 2022) used this protocol and found it safe and effective, with 16.1% mean weight loss at 68 weeks.

Geriatric (65+): no formal dose adjustment recommended, but clinical practice often uses slower titration. The STEP 5 trial included patients up to age 70 and used the standard schedule. However, older adults have higher rates of nausea and slower gastric emptying at baseline, so many providers extend each dose tier to 6 weeks instead of 4 in patients over 70. This is not protocol, but it's common practice.

Renal impairment: no dose adjustment needed. Semaglutide is metabolized by proteolysis, not renal excretion. The FLOW trial (Perkovic et al., NEJM 2024) studied semaglutide in patients with chronic kidney disease and used standard dosing.

Hepatic impairment: no dose adjustment needed for mild to moderate impairment. Severe hepatic impairment has not been studied, so use caution and consider slower titration.

How to calculate your total monthly dose cost

Compounded semaglutide is priced per vial, not per dose. The cost per milligram depends on the vial size and the dose you're taking.

Example calculation for a patient on 1.0 mg weekly:

• Vial: 10 mg total, concentration 10 mg/mL (1 mL total volume), cost $200
• Dose: 1.0 mg weekly = 10 units = 0.10 mL per injection
• Vial contains 10 injections (1 mL ÷ 0.10 mL per injection)
• Monthly cost: $200 per vial ÷ 10 weeks per vial × 4.33 weeks per month = $86.60 per month

Same patient on 2.4 mg weekly:

• Dose: 2.4 mg weekly = 24 units = 0.24 mL per injection
• Vial contains 4.17 injections (1 mL ÷ 0.24 mL per injection)
• Monthly cost: $200 per vial ÷ 4.17 weeks per vial × 4.33 weeks per month = $207.70 per month

The cost more than doubles when going from 1.0 mg to 2.4 mg because you're using 2.4 times as much medication per week. This is why some patients resist titrating to the maximum dose. The clinical question is whether the additional weight loss justifies the additional cost. For most patients, it does.

Brand-name pricing is flat per pen, regardless of dose, because each pen contains only one month's supply of a single dose tier. A Wegovy 2.4 mg pen costs the same per month as a 1.0 mg pen (both around $1,350 retail before insurance).

When to call your provider about dosing

Contact your provider within 24 hours if:

• Vomiting persists for more than 24 hours or occurs more than 4 times in one day
• Severe abdominal pain that doesn't resolve within 6 hours, especially if radiating to the back (possible pancreatitis)
• Signs of gallbladder issues: right upper quadrant pain, nausea after fatty meals, jaundice
• Symptoms of hypoglycemia in a non-diabetic patient: shakiness, confusion, sweating, heart palpitations
• Suspected dose error resulting in a 2x or greater over-dose
• Allergic reaction: hives, facial swelling, difficulty breathing (call 911 for this one, not your provider)

Most side effects (nausea, constipation, fatigue, headache) are manageable with supportive care and don't require dose changes. But the symptoms above suggest either a complication or a dose that's too high for your current tolerance.

FAQ

What is the starting dose of semaglutide for weight loss?

The starting dose is 0.25 mg once weekly for the first 4 weeks. This dose is sub-therapeutic and exists only to allow gastrointestinal adaptation. Weight loss during the first month is minimal, typically 1-2 pounds, mostly water weight.

How long do I stay at each semaglutide dose?

Each dose tier lasts 4 weeks before escalating to the next level, assuming you tolerate the current dose without persistent nausea or vomiting. The full titration from 0.25 mg to 2.4 mg takes 20 weeks (5 months).

Can I skip the 0.25 mg starting dose and go straight to 0.5 mg?

Not recommended. Patients who skip the 0.25 mg lead-in experience nausea rates above 60% in the first month, compared to 20% with proper titration. The 4-week adaptation period significantly improves tolerability.

What is the maximum dose of semaglutide?

The FDA-approved maximum dose for weight management is 2.4 mg once weekly. Doses above this are off-label and not supported by clinical trial data. The dose-response curve flattens above 2.0 mg, meaning higher doses provide minimal additional benefit.

How many units is 1.0 mg of semaglutide?

At the most common compounded concentration of 10 mg/mL, 1.0 mg equals 10 units on a U-100 insulin syringe. At 5 mg/mL it's 20 units. At 20 mg/mL it's 5 units. The unit count depends entirely on your vial's concentration.

Can I stay at 1.0 mg instead of going up to 2.4 mg?

If you reach your goal weight at 1.0 mg and maintain it for 12+ weeks, staying at 1.0 mg is appropriate. But if you plateau below your goal weight, escalating to 1.7 mg or 2.4 mg typically produces an additional 5-8 pounds of loss. The decision should be clinical, not based on cost or convenience.

What happens if I miss a dose?

If you remember within 5 days of your scheduled dose day, take it as soon as you remember and resume your weekly schedule from that new day. If more than 5 days have passed, skip the missed dose entirely and take the next dose on your regular schedule. Don't double up.

How do I convert semaglutide milligrams to milliliters?

Divide the milligram dose by the concentration in mg/mL. For example, 1.7 mg at 10 mg/mL concentration is 1.7 ÷ 10 = 0.17 mL. To convert to syringe units, multiply the milliliter volume by 100 (because U-100 syringes have 100 units per mL).

Is 2.0 mg of semaglutide the same as 2.4 mg?

No. The 2.0 mg dose is the maximum approved for type 2 diabetes (Ozempic). The 2.4 mg dose is the maximum for weight management (Wegovy). The 0.4 mg difference produces approximately 2-3 additional percentage points of weight loss in clinical trials.

Can I take semaglutide twice a week at a lower dose?

The medication is designed for once-weekly dosing based on its 7-day half-life. Splitting the weekly dose into two smaller injections is not studied and not recommended. Some patients do this to manage side effects, but it should only be done under provider guidance.

Do I need to increase my dose if I stop losing weight?

Not necessarily. Weight-loss plateaus are normal after 6-9 months on any weight-loss medication due to metabolic adaptation. If you're already at 2.4 mg, increasing the dose further is off-label and unlikely to break the plateau. Increasing activity or adjusting diet is more effective.

How long can I stay on semaglutide?

The STEP trials followed patients for 68 weeks (16 months). The STEP 5 trial extended to 104 weeks (2 years) and showed continued weight maintenance with no new safety signals. Long-term use beyond 2 years is common in clinical practice but not yet studied in formal trials. Most patients require ongoing treatment to maintain weight loss.

Related guides

• The Complete Tirzepatide Dosing Chart: Titration, Conversions, and Maintenance Doses
• Semaglutide Dosage Chart: Standard Titration Schedule and Unit Conversions for Every Common Concentration
• Compounded Semaglutide Dosing Chart: Unit Conversions for Every Concentration
• What Are the Doses of Semaglutide? A Complete Guide to FDA-Approved and Compounded Dosing Schedules
• Tirzepatide 10 mg: The Complete Dosing Guide, Unit Conversions, and Clinical Context
• What Is the Correct Metformin Starting Dose? A Complete Guide to Initial Dosing, Titration Schedules, and Formulation Differences
• Tool: dosage calculator

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Weghuber D et al. Once-Weekly Semaglutide in Adolescents with Obesity. New England Journal of Medicine. 2022.
3. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
4. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
5. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
6. Perkovic V et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. New England Journal of Medicine. 2024.
7. FDA Adverse Event Reporting System (FAERS) Public Dashboard. Q4 2024 extract. Accessed April 2026.
8. Kushner RF et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity. 2020.
9. Lingvay I et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes & Endocrinology. 2019.
10. Aroda VR et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes & Endocrinology. 2017.
11. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
12. Knop FK et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023.
13. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
14. U.S. Pharmacopeia. General Chapter 1151: Pharmaceutical Dosage Forms. USP 44-NF 39. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide is not FDA-approved. It is prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.